TriSalus Life Sciences operates a focused medtech business model centered on its proprietary PEDD platform embodied in the TriNav device family, generating revenue primarily through device sales supported by clinical and reimbursement evidence. The technology is differentiated by its pressure-enabl…
TriSalus Life Sciences (TLSI) Q1 2025: 42% Revenue Growth Driven by PEDD Platform Expansion Amid Strategic Investment
TriSalus Life Sciences accelerated its commercial momentum with a 42% year-over-year revenue increase, fueled by expanded adoption of its Pressure-Enabled Drug Delivery (PEDD) platform and new reimbursement codes. The company is investing heavily in sales force expansion and clinical registries, prioritizing long-term growth over near-term profitability. These strategic moves set the stage for broadening clinical applications and a scalable commercial footprint in interventional oncology.
Summary
- Commercial Expansion Accelerates: PEDD platform adoption deepens with new accounts and increased utilization per account.
- Strategic Investment Prioritized: Capital allocation focuses on sales force growth and clinical registries to support new indications.
- Partnership Shift for Nelitolimod: Completion of Phase 1 trials transitions immunotherapeutic candidate toward external development partnerships.
Business Overview
TriSalus Life Sciences is a medical technology company specializing in oncology, integrating proprietary drug delivery devices with standard-of-care therapies to treat solid tumors. Its core revenue driver is the TriNav system, which utilizes the Pressure-Enabled Drug Delivery (PEDD) technology to improve therapeutic delivery in liver and pancreatic cancers. The company's business model centers on device sales, clinical expansion, and investigational immunotherapeutics, with ongoing development of new clinical applications and partnerships.
Performance Analysis
In Q1 2025, TriSalus reported $9.2 million in net sales, marking a 42% increase year-over-year and an 11% sequential rise from Q4 2024. This growth is attributed to expanded sales resources, increased market share, and deeper penetration into the liver embolization market, where TriNav holds a 10% procedural market share. The company added approximately 32 new accounts, reaching around 300 total, and saw utilization gains across existing customers, indicating both breadth and depth in commercial engagement.
Gross margins held steady at 84%, slightly below the prior year’s 85%, primarily due to temporary production disruptions related to a clean room expansion completed in March. Operating losses narrowed to $7.3 million from $11.7 million in the prior year period, driven by increased revenue and a 44% reduction in research and development expenses as Nelitolimod clinical trials wind down. Adjusted EBITDA losses improved significantly to $5.5 million from $10.4 million, reflecting operational leverage despite increased stock compensation costs.
- Revenue Growth Supported by Market Adoption: 39% increase in unique ordering accounts and expanded use of TriNav in liver and emerging indications.
- Margin Pressure Temporary and Facility Ready for Growth: Clean room expansion impacted Q1 gross margin but enhances production capacity for the next five years.
- Cost Reduction in R&D Offsets Commercial Investment: Nelitolimod trial completion reduces clinical spend, partially balancing sales force expansion costs.
Overall, TriSalus demonstrates strong commercial execution with improving operational efficiency, positioning itself for sustained revenue growth despite deliberate investment-driven margin pressure.
Executive Commentary
"We believe we're just beginning to realize the full potential of over a decade of hard work, work that now positions us for multiple commercial and clinical catalysts in the coming year."
Mary Zella, President and Chief Executive Officer
"Our revenue, solely driven by the success of the TriNav device in the U.S., reached $9.2 million, representing a 42% increase compared to the same period in 2024 and 11% sequentially compared to the fourth quarter."
James Young, Chief Financial Officer
Strategic Positioning
1. Expanding PEDD Platform Adoption Across Solid Tumors
TriSalus is aggressively growing market share in liver embolization while extending PEDD technology into new clinical applications such as thyroid artery embolization and uterine fibroid embolization. The launch of TriNav LV and TriGuide devices broadens the vessel size range treated, enabling penetration into larger tumors and novel indications. This multi-pronged approach aims to establish PEDD as a versatile platform across interventional oncology.
2. Commercial Footprint and Sales Force Scaling
The company currently employs approximately 45 clinical specialists and sales representatives, targeting an increase to 60-70 over the next 18 to 24 months. Hiring is focused on candidates with clinical and technical expertise capable of navigating complex therapeutic landscapes. This deliberate scaling aligns with anticipated volume growth and geographic coverage expansion, underpinning the goal of capturing 80% of procedural volume across 400 target hospitals.
3. Leveraging Reimbursement Advances
The recent issuance of HCPCS code C8004 by CMS doubles reimbursable use cases for TriNav, covering both mapping and treatment in radioembolization. Early physician feedback is highly favorable, reducing barriers to broader adoption and enabling more consistent utilization. This reimbursement clarity is a critical inflection point for commercial acceleration.
4. Transitioning Nelitolimod Toward Partnership Development
With Phase 1 trials completed, Nelitolimod development is shifting to a partnership model, allowing TriSalus to cease internal development expenses by year-end. The immunotherapeutic’s unique delivery via PEDD technology targets the tumor microenvironment to stimulate immune response, particularly in checkpoint refractory patients. This strategic pivot preserves long-term value while focusing internal resources on core device growth.
5. Data-Driven Clinical Validation and Registries
TriSalus is investing in real-world health economics and outcomes research (HEOR) and multiple registries to build evidence across new indications. Early data from over 600 PEDD-treated patients demonstrate reduced hospital admissions and improved patient fatigue, supporting clinical and economic value propositions. Registries in genicular artery embolization and uterine fibroid embolization will further substantiate efficacy and inform guideline inclusion.
Key Considerations
TriSalus is executing a growth strategy that balances commercial expansion with foundational clinical validation and reimbursement support. Key considerations for investors include:
- Sales Force Investment Impact: Expansion will drive revenue growth but delays profitability, with meaningful volume gains expected in late 2025 and beyond.
- Reimbursement as a Growth Catalyst: New mapping code adoption is a significant enabler for utilization increases and broader clinical acceptance.
- Product Portfolio Diversification: Launches of TriNav LV, TriGuide, and upcoming TriNavFlex enhance procedural versatility and market reach.
- Clinical Data as Differentiator: Ongoing HEOR and registry results underpin physician adoption and payer support.
- Capital Structure Simplification: Preferred share conversion agreement improves shareholder alignment and reduces future dilution risks.
Risks
Risks include potential delays in sales force ramp-up and slower-than-expected adoption of new clinical applications. Regulatory or reimbursement changes could impact market access. The partnership outcome for Nelitolimod remains uncertain, and failure to secure favorable deals could limit value realization. Production disruptions or cost overruns related to manufacturing expansion also pose risks to margin stability.
Forward Outlook
For Q2 2025, TriSalus expects continued revenue growth consistent with its 50% full-year target, supported by ongoing sales force additions and increased utilization. Gross margins are anticipated to improve as clean room expansion effects normalize. The company does not expect adjusted EBITDA or cash flow positivity in 2025 due to strategic investments but projects positive cash flow in the first half of 2026.
- Revenue growth of at least 50% for full-year 2025.
- Gross margin recovery toward upper 80% range following production normalization.
Management emphasized that investments in commercial resources and clinical registries will expand addressable markets and drive long-term value creation despite near-term margin pressure.
Takeaways
TriSalus is capitalizing on a strong commercial foundation to accelerate growth through strategic investments and clinical innovation. Key takeaways for investors include:
- Commercial Momentum Is Robust: The 42% revenue growth and 39% increase in unique ordering accounts reflect successful market penetration and physician adoption of PEDD technology.
- Strategic Investment Balances Growth and Profitability: Deliberate sales force expansion and clinical registry development support scaling but defer adjusted EBITDA and cash flow breakeven into 2026.
- Partnership Model for Nelitolimod Unlocks Focus: Transitioning immunotherapeutic development externally allows the company to concentrate resources on expanding the PEDD platform and broadening clinical indications.
Conclusion
TriSalus Life Sciences delivered a strong first quarter with accelerating revenue growth driven by expanded commercial adoption and reimbursement advances. The company is investing strategically in sales force and clinical validation to support long-term growth, accepting near-term margin pressure. Its shift toward partnerships for Nelitolimod development further refines focus on core device innovation, positioning TriSalus for sustained value creation in interventional oncology.
Industry Read-Through
TriSalus’ results highlight the critical role of reimbursement clarity and clinical evidence in driving medtech adoption within interventional oncology. The expansion of device portfolios to address a broader range of vascular anatomies and tumor types reflects a growing trend toward platform technologies that enable precision drug delivery. The company’s move to partner on immunotherapeutics underscores the increasing convergence of device and pharmaceutical innovation in oncology, a dynamic other medtech players should monitor closely. Additionally, the emphasis on real-world outcomes and registries signals a sector-wide shift toward evidence-based adoption and payer engagement strategies.